In addition to B3GNT3 in breast cancer and GLT1D1 in NHLs that affect glycosylation of PD‐L1, other glycosyltransferase enzymes such as GCNT3 have also been shown to impact the clinical outcome of colon and ovarian cancers, and are considered as a prognostic biomarker for the identification of early‐stage colon cancer patients at high risk of relapse (Fernandez et al., 2018; Gonzalez‐Vallinas et al., 2015). This evidence concerns the gene GCNT3 and ovarian carcinoma.